BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

177 related articles for article (PubMed ID: 14981927)

  • 21. Mutant epidermal growth factor receptor (EGFRvIII) contributes to head and neck cancer growth and resistance to EGFR targeting.
    Sok JC; Coppelli FM; Thomas SM; Lango MN; Xi S; Hunt JL; Freilino ML; Graner MW; Wikstrand CJ; Bigner DD; Gooding WE; Furnari FB; Grandis JR
    Clin Cancer Res; 2006 Sep; 12(17):5064-73. PubMed ID: 16951222
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Recent advances in head and neck cancer therapy: the role of new cytotoxic and molecular-targeted agents.
    Caponigro F; Milano A; Basile M; Ionna F; Iaffaioli RV
    Curr Opin Oncol; 2006 May; 18(3):247-52. PubMed ID: 16552236
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Docetaxel, cisplatin, and 5-fluorouracil-based induction chemotherapy in patients with locally advanced squamous cell carcinoma of the head and neck: the Dana Farber Cancer Institute experience.
    Haddad R; Colevas AD; Tishler R; Busse P; Goguen L; Sullivan C; Norris CM; Lake-Willcutt B; Case MA; Costello R; Posner M
    Cancer; 2003 Jan; 97(2):412-8. PubMed ID: 12518365
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Concurrent weekly docetaxel and concomitant boost radiation therapy in the treatment of locally advanced squamous cell cancer of the head and neck.
    Tishler RB; Posner MR; Norris CM; Mahadevan A; Sullivan C; Goguen L; Wirth LJ; Costello R; Case M; Stowell S; Sammartino D; Busse PM; Haddad RI
    Int J Radiat Oncol Biol Phys; 2006 Jul; 65(4):1036-44. PubMed ID: 16682134
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Docetaxel in the management of patients with head and neck squamous cell carcinoma.
    Bernier J; Vrieling C
    Expert Rev Anticancer Ther; 2008 Jul; 8(7):1023-32. PubMed ID: 18588449
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Randomized controlled phase II comparison study of concurrent chemoradiotherapy with docetaxel, cisplatin, and 5-fluorouracil versus CCRT with cisplatin, 5-fluorouracil, methotrexate and leucovorin in patients with locally advanced squamous cell carcinoma of the head and neck.
    Tsukuda M; Ishitoya J; Matsuda H; Horiuchi C; Taguchi T; Takahashi M; Nishimura G; Kawakami M; Watanabe M; Niho T; Kawano T; Ikeda Y; Sakuma Y; Shiono O; Komatsu M
    Cancer Chemother Pharmacol; 2010 Sep; 66(4):729-36. PubMed ID: 20033810
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Phase I trial of combined chemotherapy with docetaxel, cisplatin, and 5-fluorouracil for patients with locally advanced squamous cell carcinoma of the head and neck.
    Tsukuda M; Mikami Y; Tanigaki Y; Katori H; Horiuchi C; Ikeda Y; Taguchi T; Ono M; Yoshida T; Sakuma Y; Aikoh K
    Int J Clin Oncol; 2004 Jun; 9(3):161-6. PubMed ID: 15221599
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The role of induction chemotherapy in the curative treatment of squamous cell cancer of the head and neck.
    Posner MR; Colevas AD; Tishler RB
    Semin Oncol; 2000 Aug; 27(4 Suppl 8):13-24. PubMed ID: 10952434
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Prognosis of esophageal squamous cell carcinoma in patients positive for human epidermal growth factor receptor family can be improved by initial chemotherapy with docetaxel, fluorouracil, and cisplatin.
    Yamamoto Y; Yamai H; Seike J; Yoshida T; Takechi H; Furukita Y; Kajiura K; Minato T; Bando Y; Tangoku A
    Ann Surg Oncol; 2012 Mar; 19(3):757-65. PubMed ID: 21947696
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Efficacy of multidrug superselective intra-arterial chemotherapy (docetaxel, cisplatin, and 5-fluorouracil) using the Seldinger technique for tongue cancer.
    Furusaka T; Asakawa T; Tanaka A; Matsuda H; Ikeda M
    Acta Otolaryngol; 2012 Oct; 132(10):1108-14. PubMed ID: 22998559
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Induction chemotherapy for head and neck cancer: recent data.
    Vokes EE
    Oncologist; 2010; 15 Suppl 3():3-7. PubMed ID: 21036882
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Neoadjuvant docetaxel, cisplatin, 5-fluorouracil before concurrent chemoradiotherapy in locally advanced squamous cell carcinoma of the head and neck versus concomitant chemoradiotherapy: a phase II feasibility study.
    Ghi MG; Paccagnella A; D'Amanzo P; Mione CA; Fasan S; Paro S; Mastromauro C; Carnuccio R; Turcato G; Gatti C; Pallini A; Nascimben O; Biason R; Oniga F; Medici M; Rossi F; Fila G
    Int J Radiat Oncol Biol Phys; 2004 Jun; 59(2):481-7. PubMed ID: 15145166
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Antitumor effect and potentiation of cytotoxic drugs activity in human cancer cells by ZD-1839 (Iressa), an epidermal growth factor receptor-selective tyrosine kinase inhibitor.
    Ciardiello F; Caputo R; Bianco R; Damiano V; Pomatico G; De Placido S; Bianco AR; Tortora G
    Clin Cancer Res; 2000 May; 6(5):2053-63. PubMed ID: 10815932
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Induction chemotherapy with cisplatin/docetaxel versus cisplatin/5-fluorouracil for locally advanced squamous cell carcinoma of the head and neck: a randomised phase II study.
    Fonseca E; Grau JJ; Sastre J; García-Gómez JM; Rueda A; Pastor M; Lara MA; Navalón M; Berrocal A; Tisaire JL; Cruz JJ
    Eur J Cancer; 2005 Jun; 41(9):1254-60. PubMed ID: 15908196
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Phase II study of induction and adjuvant chemotherapy for squamous cell carcinoma of the head and neck. A long-term analysis for the Illinois Cancer Center.
    Athanasiadis I; Taylor S; Vokes EE; Pelzer HJ; Rademaker A; Mittal BB; Ganzenko N; Blough R; Lester EP; Kies MS
    Cancer; 1997 Feb; 79(3):588-94. PubMed ID: 9028372
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Head and neck cancer: integrating anti-EGFR treatment with standard therapy.
    Kies MS
    J Natl Compr Canc Netw; 2004 Sep; 2 Suppl 2():S52-9. PubMed ID: 19780246
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Small interfering RNA targeting epidermal growth factor receptor enhances chemosensitivity to cisplatin, 5-fluorouracil and docetaxel in head and neck squamous cell carcinoma.
    Nozawa H; Tadakuma T; Ono T; Sato M; Hiroi S; Masumoto K; Sato Y
    Cancer Sci; 2006 Oct; 97(10):1115-24. PubMed ID: 16984384
    [TBL] [Abstract][Full Text] [Related]  

  • 38. C225 antiepidermal growth factor receptor antibody enhances the efficacy of docetaxel chemoradiotherapy.
    Nakata E; Hunter N; Mason K; Fan Z; Ang KK; Milas L
    Int J Radiat Oncol Biol Phys; 2004 Jul; 59(4):1163-73. PubMed ID: 15234052
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Transforming growth factor alpha stimulation of mucosal tissue cultures from head and neck squamous cell carcinoma patients increases chemoresistance to cisplatin.
    Baumeister P; Reiter M; Schwenk-Zieger S; Harréus U
    Chemotherapy; 2010; 56(4):268-74. PubMed ID: 20693797
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Antitumor effects of epidermal growth factor receptor antisense oligonucleotides in combination with docetaxel in squamous cell carcinoma of the head and neck.
    Niwa H; Wentzel AL; Li M; Gooding WE; Lui VW; Grandis JR
    Clin Cancer Res; 2003 Oct; 9(13):5028-35. PubMed ID: 14581378
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.